KR20240161664A - 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 - Google Patents
멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 Download PDFInfo
- Publication number
- KR20240161664A KR20240161664A KR1020247034012A KR20247034012A KR20240161664A KR 20240161664 A KR20240161664 A KR 20240161664A KR 1020247034012 A KR1020247034012 A KR 1020247034012A KR 20247034012 A KR20247034012 A KR 20247034012A KR 20240161664 A KR20240161664 A KR 20240161664A
- Authority
- KR
- South Korea
- Prior art keywords
- melphalan flufenamide
- cyclodextrin
- γcd
- pharmaceutically acceptable
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204171.9A GB202204171D0 (en) | 2022-03-24 | 2022-03-24 | Novel formulations |
| GB2204171.9 | 2022-03-24 | ||
| PCT/EP2023/057729 WO2023180565A1 (en) | 2022-03-24 | 2023-03-24 | Formulations comprising melphalan flufenamide and cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240161664A true KR20240161664A (ko) | 2024-11-12 |
Family
ID=81449463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247034012A Pending KR20240161664A (ko) | 2022-03-24 | 2023-03-24 | 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250205155A1 (https=) |
| EP (1) | EP4499049A1 (https=) |
| JP (1) | JP2025510725A (https=) |
| KR (1) | KR20240161664A (https=) |
| CN (1) | CN119053323A (https=) |
| AU (1) | AU2023241241A1 (https=) |
| CA (1) | CA3245985A1 (https=) |
| GB (1) | GB202204171D0 (https=) |
| IL (1) | IL315551A (https=) |
| MX (1) | MX2024011654A (https=) |
| WO (1) | WO2023180565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025233915A1 (en) * | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| DK2701720T3 (en) | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
-
2022
- 2022-03-24 GB GBGB2204171.9A patent/GB202204171D0/en not_active Ceased
-
2023
- 2023-03-24 WO PCT/EP2023/057729 patent/WO2023180565A1/en not_active Ceased
- 2023-03-24 JP JP2024556113A patent/JP2025510725A/ja active Pending
- 2023-03-24 IL IL315551A patent/IL315551A/en unknown
- 2023-03-24 CN CN202380035203.1A patent/CN119053323A/zh active Pending
- 2023-03-24 CA CA3245985A patent/CA3245985A1/en active Pending
- 2023-03-24 US US18/849,977 patent/US20250205155A1/en active Pending
- 2023-03-24 EP EP23720032.4A patent/EP4499049A1/en active Pending
- 2023-03-24 KR KR1020247034012A patent/KR20240161664A/ko active Pending
- 2023-03-24 AU AU2023241241A patent/AU2023241241A1/en active Pending
-
2024
- 2024-09-23 MX MX2024011654A patent/MX2024011654A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023241241A1 (en) | 2024-10-31 |
| CA3245985A1 (en) | 2023-09-28 |
| WO2023180565A1 (en) | 2023-09-28 |
| EP4499049A1 (en) | 2025-02-05 |
| US20250205155A1 (en) | 2025-06-26 |
| CN119053323A (zh) | 2024-11-29 |
| JP2025510725A (ja) | 2025-04-15 |
| MX2024011654A (es) | 2025-01-09 |
| GB202204171D0 (en) | 2022-05-11 |
| IL315551A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100941210B1 (ko) | 백금 유도체를 포함하는 제약 제제 | |
| JP6257734B2 (ja) | デシタビン誘導体製剤 | |
| ES2767880T3 (es) | Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de preparación y uso de las mismas | |
| JP6106228B2 (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液 | |
| TW201039865A (en) | Lyophilized preparations of proteasome inhibitors | |
| JP6516831B2 (ja) | シクロホスファミド液状濃縮物の製剤 | |
| US11865180B2 (en) | Levothyroxine formulations for oral use | |
| US20220047509A1 (en) | Stabilized liquid formulation of levothyroxine | |
| JP2016521731A (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| JPH11507936A (ja) | ラモトリジン含有医薬組成物 | |
| KR20240161664A (ko) | 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 | |
| EP4055005A1 (en) | Liquid melphalan composition | |
| EA052092B1 (ru) | Препараты, содержащие мелфалана флуфенамид и циклодекстрин | |
| CN111107837A (zh) | 包含西普尼莫德的肠胃外制剂 | |
| TW202412832A (zh) | 催產素配方 | |
| US8716521B2 (en) | Formulations of canfosfamide and their preparation | |
| WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
| CN120529922A (zh) | 肽药物偶联物 | |
| JP2026016486A (ja) | 安定なシクロデキストリン不含カルフィルゾミブ処方物 | |
| JP2025522933A (ja) | メルファランを含む安定した液体医薬組成物 | |
| EP3747428A1 (en) | Stable melphalan liquid injectable formulations | |
| AU2011200939B1 (en) | Formulations of Canfosfamide and their preparation | |
| TW201302755A (zh) | 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法 | |
| WO2012115655A1 (en) | Formulations of canfosfamide and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |